Highest-materiality recent filing
Tandem Diabetes terminates CCO Mark Novara without cause; last day May 18
Mark Novara, EVP & Chief Commercial Officer, notified of termination without cause on May 11, 2026.
Tandem Diabetes closes $300M zero-coupon convertible notes due 2032; net proceeds ~$290.7M
Issued $300M aggregate principal of 0.00% Convertible Senior Notes due 2032 (including $35M greenshoe exercised).
Tandem Diabetes receives FDA 510(k) clearance for SteadiSet infusion set for 7-day use
FDA cleared SteadiSet infusion set for up to seven days of use; features integrated inserter with hidden needle.
Tandem settles patent disputes with Roche, agrees to pay $36M over five years
Settlement resolves pending patent actions in France and Germany regarding t:slim X2 pump and two EP patents.
CE mark granted for Tandem Mobi insulin delivery system with Control-IQ+ technology.
FDA cleared SteadiSet infusion set for up to 3 days of use; submission by subsidiary CapBio.
Tandem and Dexcom amend agreements to integrate Sigi pump with G7 CGM for five years
On May 22, 2024, Tandem and Dexcom entered into two amended and restated agreements.
FDA clears Tandem Mobi insulin pump for pediatric use ages 2+
FDA cleared Tandem Mobi insulin pump for expanded pediatric indication in individuals two years and older.
Issued $316.25M aggregate principal amount of 1.50% Convertible Senior Notes due 2029, including full exercise of initial purchasers' option for additional $41.25M.
On May 11, 2026, Mark Novara, the Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc. (the “Company”), was notified that his employment with the Company is being terminated without cause.
On June 19, 2024, the Board of Directors of Tandem Diabetes Care, Inc. (the “Company”) approved the appointment of Jean-Claude Kyrillos as Executive Vice President, Chief Operating Officer effective June 21, 2024.
Max materiality 0.80 · Median 0.50 · Most common event earnings